Why invest in a stock whose growth outlook that lags behind the market? Investors looking for companies with extraordinary future prospects in terms of profitability and returns should look at the following high-growth stocks. Analysing the most recent financial data, I’ve created a list of companies that compare favourably in all criteria, making them potentially good additions to your portfolio.
Athenex, Inc. (NASDAQ:ATNX)
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer. Formed in 2003, and run by CEO Yiu-Nam Lau, the company employs 450 people and with the stock’s market cap sitting at USD $922.12M, it comes under the small-cap group.
ATNX’s forecasted bottom line growth is an optimistic double-digit 19.53%, driven by underlying sales, which is expected to more than double, over the next few years. Profit growth, coupled with top-line expansion, is a positive indication. This is because net income isn’t artificially inflated by unsustainable activities such as one-off cost-reductions expected in the future. ATNX’s bullish prospects on both the top and bottom lines make it an interesting stock to invest more time to understand how it can add value to your portfolio. Could this stock be your next pick? Take a look at its other fundamentals here.
Amicus Therapeutics, Inc. (NASDAQ:FOLD)
Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. Started in 2002, and now run by John Crowley, the company size now stands at 263 people and with the company’s market cap sitting at USD $2.39B, it falls under the mid-cap group.
FOLD’s projected future profit growth is a robust 43.73%, with an underlying triple-digit growth from its revenues expected over the upcoming years. An affirming signal is when net income increase is supported by top-line growth. Since net income isn’t artificially inflated by one-off initiatives such as cost-cutting, we know this profit growth is more likely to be sustainable. Moreover, the 32.78% growth in operating cash flows shows that a decent part of earnings is driven by robust cash generation from operational activities, not one-off or non-core activities. FOLD’s bullish prospects make it an interesting stock to invest more time to understand how it can add value to your portfolio. Should you add FOLD to your portfolio? I recommend researching its fundamentals here.
Second Sight Medical Products, Inc. (NASDAQ:EYES)
Second Sight Medical Products, Inc. develops, manufactures, and markets prosthetic devices to restore functional vision to blind individuals in the United States, Italy, Germany, France, and Canada. Formed in 1998, and currently lead by Jonathan McGuire, the company now has 110 employees and with the stock’s market cap sitting at USD $108.50M, it comes under the small-cap category.
Could this stock be your next pick? I recommend researching its fundamentals here.
For more financially robust companies with high growth potential to enhance your portfolio, use our free platform to explore our interactive list of these stocks.
To help readers see pass the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price sensitive company announcements.
The author is an independent contributor and at the time of publication had no position in the stocks mentioned.